GlassScriptPhysician profile
John P Whitecar
NPI 1700936002
$8,160.87
in general payments reported to CMS, 2019-2025
56 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $304 · 2022: $1,082 · 2023: $1,605 · 2024: $1,843 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,570.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $746.50 | 2019-2025 | |
| Pfizer INC. | $714.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $616.51 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $516.84 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $515.99 | 2019-2025 | Monjuvi, Monjuvi, Jakafi |
| Janssen Biotech, INC. | $474.26 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Celgene Corporation | $417.46 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Daiichi Sankyo INC. | $312.24 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $257.31 | 2019-2025 | |
| Amgen INC. | $207.49 | 2019-2023 | Vectibix, Nplate |
| Gilead Sciences, INC. | $203.88 | 2022-2025 | Trodelvy |
| Genentech USA, INC. | $189.17 | 2019-2023 | Perjeta, Phesgo |
| Adaptive Biotechnologies Corporation | $177.00 | 2023-2025 | Clonoseq |
| Exelixis INC. | $176.37 | 2019-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $174.48 | 2023-2025 | Libtayo, Lynozyfic |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $170.37 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $155.97 | 2019-2025 | Imfinzi, Enhertu |
| Abbvie INC. | $149.12 | 2019-2025 | Venclexta |
| Genzyme Corporation | $146.62 | 2019-2025 | |
| Eisai INC. | $145.29 | 2019-2024 | |
| Seagen INC. | $130.05 | 2019-2023 | Adcetris, Tivdak |
| Taiho Oncology, INC. | $121.70 | 2022-2025 | |
| Blueprint Medicines Corporation | $100.77 | 2022 | |
| Beigene USA, INC. | $91.62 | 2023-2024 | Brukinsa |
| Astellas Pharma US INC | $77.33 | 2024-2025 | Vyloy, Xospata, Padcev |
| Alexion Pharmaceuticals, INC. | $77.18 | 2022-2023 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $72.92 | 2022-2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $64.72 | 2019-2020 | |
| Coherus Oncology, INC. | $64.20 | 2024-2025 | Loqtorzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.72 | 2024-2025 | Fruzaqla, Iclusig |
| Emd Serono, INC. | $56.80 | 2024-2025 | |
| Legend Biotech USA INC. | $54.61 | 2024-2025 | Carvykti |
| Lilly USA, LLC | $50.25 | 2019-2025 | Verzenio, Jaypirca |
| Array Biopharma INC | $47.71 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Deciphera Pharmaceuticals INC. | $46.62 | 2024 | Qinlock |
| Stemline Therapeutics INC. | $45.29 | 2023-2024 | Orserdu |
| Tesaro, INC. | $44.85 | 2019 | |
| Genmab U.S., INC. | $39.94 | 2024-2025 | Epkinly |
| Servier Pharmaceuticals LLC | $39.15 | 2025 | |
| Sanofi-Aventis U.S. LLC | $34.21 | 2019-2020 | |
| Shield Therapeutics INC | $29.60 | 2023-2024 | Accrufer |
| Recordati_rare_diseases_inc. | $29.52 | 2025 | Enjaymo |
| Clovis Oncology, INC. | $28.94 | 2019 | |
| Beone Medicines USA, INC. | $26.62 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $26.03 | 2022 | |
| Tersera Therapeutics LLC | $23.64 | 2025 | Zoladex |
| Myriad Genetic Laboratories, INC. | $20.60 | 2025 | Myrisk |
| Geron Corporation | $17.66 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $17.49 | 2025 | Pyrukynd |
| Verastem, INC. | $17.27 | 2019 | |
| Global Blood Therapeutics, INC. | $16.34 | 2022 | |
| Karyopharm Therapeutics INC. | $14.74 | 2022 | |
| Aveo Pharmaceuticals, INC. | $14.06 | 2022 | |
| Pharmaessentia USA Corporation | $13.87 | 2025 | Besremi |
| Kite Pharma, INC. | $12.75 | 2023 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Whitecar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.